Novartis Magyarország

What Novartis Magyarország does

Novartis Magyarország (legal name: Novartis Hungária Kft.) is the Hungarian operating subsidiary of Swiss multinational pharmaceutical company Novartis AG (NYSE: NVS). The entity is headquartered in Budapest at Bartók Béla út 43-47 and operates with approximately 41 employees focused on commercial, medical affairs, and clinical trial activities in Hungary. It is a privately-held limited liability company (Kft.) wholly owned by Novartis AG, which was formed in 1996 through the merger of Ciba-Geigy and Sandoz.

The subsidiary promotes and distributes Novartis AG's prescription pharmaceutical portfolio across six therapeutic areas: dermatology, hematology, cardiology, neurology, oncology, and rheumatology. Its product platform includes the Novartis Orvosportál (Doctor Portal), a gated digital platform providing Hungarian healthcare professionals with product information, therapeutic-area updates, clinical trial information, medical events, and professional education resources. The subsidiary also operates clinical trial services in Hungary, supporting trial sites, patients, and investigators across the parent company's global pipeline. Recent awareness campaigns have covered Cancer Day, nephrology, and cardiovascular risk.

Commercially, Novartis Magyarország generates revenue through pharmaceutical product sales to Hungarian hospitals, pharmacies, and healthcare professionals, with distribution subject to national healthcare regulations and reimbursement schemes. The go-to-market model is enterprise field sales targeting physicians and healthcare institutions, supported by the Orvosportál digital channel and PR-driven awareness campaigns addressing patients and the broader public. Pricing is regulated through national healthcare systems and is not publicly disclosed. The entity operates as part of Novartis AG's global network reaching approximately 800 million people worldwide with its medicines.

Name

Novartis Magyarország

Legal name

Novartis Hungária Kft.

Website

https://novartis.hu

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Novartis Magyarország is the Hungarian subsidiary of Novartis AG, distributing prescription pharmaceuticals across dermatology, hematology, cardiology, neurology, oncology, and rheumatology to Hungarian healthcare professionals, hospitals, and patients through enterprise field sales and the Orvosportál doctor portal.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Medical Oncology (HLAKAFAB), Specialty Pharmacy & Biologics Distribution (CRAOAHAD)

Keywords

• Prescription pharmaceuticals
• Oncology treatments
• Clinical trial services
• Specialty medicines
• Healthcare professional portal

Headquarters

HQ city

Budapest

HQ country

Hungary

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Pharmaceutical product sales: Novartis generates revenue through the sale of prescription pharmaceutical products across therapeutic areas including oncology, cardiology, neurology, dermatology, hematology, and rheumatology. Products are distributed through healthcare institutions, pharmacies, and directly to healthcare professionals.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Novartis Magyarország distributes and sells prescription pharmaceutical products across six therapeutic areas — dermatology, hematology, cardiology, neurology, oncology, and rheumatology — to hospitals, pharmacies, and healthcare professionals in Hungary. The subsidiary also runs clinical trial activities locally and operates the Novartis Orvosportál (Doctor Portal) digital platform that provides Hungarian healthcare professionals with product information, therapeutic-area news, events, and professional resources.

Product overview

Novartis Magyarország operates as a pharmaceutical company offering a platform-based approach with the Novartis Orvosportál (Doctor Portal) as the primary digital platform for healthcare professionals. The portfolio includes therapeutic areas spanning Cardiology, Dermatology, Hematology, Neurology (including Multiple Sclerosis), Oncology, and Rheumatology. The company also provides access to its global clinical pipeline and marketed product portfolio through dedicated platforms. Clinical trial services are offered for patients, healthcare professionals, and researchers in Hungary. The core offering consists of breakthrough medicines across multiple therapeutic areas, supported by digital platforms for medical information and professional engagement.

Differentiator

Problem solved

Functional benefit

Products and services

• Novartis Orvosportál (Doctor Portal) Registration-protected digital platform for Hungarian physicians and healthcare professionals providing product information, therapeutic-area news, events, and professional resources related to Novartis medicines.
• Klinikai Vizsgálatok (Clinical Trials) — Hungary Clinical-trial management and information services in Hungary for patients, caregivers, healthcare professionals, and investigator sites participating in Novartis-sponsored clinical research.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves4 records

Expansion highlights3 records

Direct peers

• Bayer Hungary: Hungarian subsidiary of Bayer, operating in pharmaceuticals (cardiology, women's health, oncology) alongside consumer health. Comparable in therapeutic area overlap and country-level pharmaceutical distribution.
• Roche Magyarország: Hungarian subsidiary of Roche, a major oncology and diagnostics competitor. Directly comparable in business model, therapeutic area focus, and HCP engagement approach in the Hungarian market.
• Johnson & Johnson Hungary: Hungarian subsidiary of J&J's pharmaceutical (Janssen) division, covering oncology, immunology, and neuroscience. Directly comparable as a multi-therapeutic pharma subsidiary with Hungarian field sales operations.
• GSK Hungary: Hungarian subsidiary of GSK, operating in specialty medicines, vaccines, and HIV. Comparable as a country-level pharmaceutical subsidiary serving the Hungarian market with similar GTM motion.
• AstraZeneca Hungary: Hungarian subsidiary of AstraZeneca, focused on oncology, cardiovascular, renal, and respiratory therapies. Comparable therapeutic area overlap and physician-targeted sales model in Hungary.
• Sanofi-Aventis Magyarország: Hungarian subsidiary of Sanofi, distributing prescription medicines across specialty care, vaccines, and rare diseases. Comparable as a country-level pharma subsidiary operating with similar distribution and HCP engagement models.
• Pfizer Hungary: Hungarian subsidiary of Pfizer Inc., distributing the same innovator pharmaceutical portfolio targeting Hungarian physicians and hospitals across oncology, vaccines, and specialty care. Directly comparable as a country-level operating arm of a top-tier global pharma.
• AbbVie Hungary: Hungarian subsidiary of AbbVie, focused on immunology, oncology, neuroscience, and aesthetics. Comparable as a specialty pharma subsidiary with strong hospital-channel presence and overlapping therapeutic areas (immunology, oncology).
• Eli Lilly Hungary: Hungarian subsidiary of Eli Lilly, focused on oncology, diabetes, neuroscience, and immunology. Comparable as a multi-therapeutic pharma subsidiary operating through field sales and HCP engagement.
• Merck Sharp & Dohme Hungary: Hungarian subsidiary of Merck & Co., focused on oncology, vaccines, and specialty medicines. Comparable in therapeutic focus, distribution via hospitals and pharmacies, and HCP engagement.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/novartis
• YouTubeyoutube.com/novartis
• Facebookfacebook.com/novartis
• LinkedInlinkedin.com/company/novartis-magyarorszag
• Instagraminstagram.com/novartis

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novartis Magyarország